Within 24 h of the symptoms onset, eligible patients (minor ischemic stroke or high-risk TIA) only carrying CYP2C19 loss-of-function alleles were included in the CHANCE-2 trial. The gene discussed is CYP2C19; the disease is transient ischemic attack.